HLA-DRα1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis

CD74, the cell-surface form of the MHC class II invariant chain, is a key inflammatory factor that is involved in various immune-mediated diseases as part of the macrophage migration inhibitory factor (MIF) binding complex. However, little is known about the natural regulators of CD74 in this context. In order to study the role of the HLA-DR molecule in regulating CD74, we used the HLA-DRα1 domain, which was shown to bind to and downregulate CD74 on CD11b+ monocytes. We found that DRα1 directly inhibited binding of MIF to CD74 and blocked its downstream inflammatory effects in the spinal cord of mice with experimental autoimmune encephalomyelitis (EAE). Potency of the DRα1 domain could be destroyed by trypsin digestion but enhanced by addition of a peptide extension (myelin oligodendrocyte glycoprotein [MOG]-35–55 peptide) that provided secondary structure not present in DRα1. These data suggest a conformationally sensitive determinant on DRα1-MOG that is responsible for optimal binding to CD74 and antagonism of MIF effects, resulting in reduced axonal damage and reversal of ongoing clinical and histological signs of EAE. These results demonstrate natural antagonist activity of DRα1 for MIF that was strongly potentiated by the MOG peptide extension, resulting in a novel therapeutic, DRα1–MOG-35–55, that within the limitations of the EAE model may have the potential to treat autoimmune diseases such as multiple sclerosis.

[1]  N. Alkayed,et al.  A novel HLA-DRα1-MOG-35-55 construct treats experimental stroke , 2014, Metabolic Brain Disease.

[2]  Guillaume Lamour,et al.  Promiscuity as a functional trait: intrinsically disordered regions as central players of interactomes. , 2013, The Biochemical journal.

[3]  Vladimir N. Uversky,et al.  The roles of intrinsic disorder in protein interaction networks , 2013 .

[4]  Jessica K. Alexander,et al.  Macrophage Migration Inhibitory Factor Potentiates Autoimmune-Mediated Neuroinflammation , 2013, The Journal of Immunology.

[5]  L. Leng,et al.  CD74-dependent deregulation of the tumor suppressor scribble in human epithelial and breast cancer cells. , 2013, Neoplasia.

[6]  D. Bourdette,et al.  Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects , 2013, European journal of immunology.

[7]  Shayne F. Andrew,et al.  A novel regulatory pathway for autoimmune disease: binding of partial MHC class II constructs to monocytes reduces CD74 expression and induces both specific and bystander T-cell tolerance. , 2013, Journal of Autoimmunity.

[8]  K. Wucherpfennig,et al.  Crystal Structure of the HLA-DM–HLA-DR1 Complex Defines Mechanisms for Rapid Peptide Selection , 2012, Cell.

[9]  L. Stern,et al.  Conformational lability in the class II MHC 310 helix and adjacent extended strand dictate HLA-DM susceptibility and peptide exchange , 2011, Proceedings of the National Academy of Sciences.

[10]  M. Zacharias,et al.  Stoichiometry of HLA Class II-Invariant Chain Oligomers , 2011, PloS one.

[11]  Andreas Schlundt,et al.  Bidirectional binding of invariant chain peptides to an MHC class II molecule , 2010, Proceedings of the National Academy of Sciences.

[12]  O. McCarty,et al.  Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis , 2010, Journal of Neuroimmunology.

[13]  J. Bernhagen,et al.  A functional heteromeric MIF receptor formed by CD74 and CXCR4 , 2009, FEBS letters.

[14]  H. Dyson,et al.  Linking folding and binding. , 2009, Current opinion in structural biology.

[15]  Anthony Cruz,et al.  Model for the Peptide-Free Conformation of Class II MHC Proteins , 2008, PloS one.

[16]  D. Goldenberg,et al.  CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms , 2007, Clinical Cancer Research.

[17]  J. Bernhagen,et al.  MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment , 2007, Nature Medicine.

[18]  L. Leng,et al.  CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. , 2006, Immunity.

[19]  N. Koch,et al.  Assembly of major histocompatibility complex class II subunits with invariant chain , 2005, FEBS letters.

[20]  A. Satoskar,et al.  Cutting Edge: Macrophage Migration Inhibitory Factor Is Necessary for Progression of Experimental Autoimmune Encephalomyelitis1 , 2005, The Journal of Immunology.

[21]  Michelle Palmer,et al.  Monoclonal Antibodies Specific for the Empty Conformation of HLA-DR1 Reveal Aspects of the Conformational Change Associated with Peptide Binding* , 2004, Journal of Biological Chemistry.

[22]  E. Bergseng,et al.  Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Calandra,et al.  Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.

[24]  A. Llera,et al.  Functional Analysis of the TCR Binding Domain of Toxic Shock Syndrome Toxin-1 Predicts Further Diversity in MHC Class II/Superantigen/TCR Ternary Complexes 1 , 2003, The Journal of Immunology.

[25]  L. Fugger,et al.  Recombinant TCR Ligand Induces Tolerance to Myelin Oligodendrocyte Glycoprotein 35-55 Peptide and Reverses Clinical and Histological Signs of Chronic Experimental Autoimmune Encephalomyelitis in HLA-DR2 Transgenic Mice1 , 2003, The Journal of Immunology.

[26]  L. Leng,et al.  MIF Signal Transduction Initiated by Binding to CD74 , 2003, The Journal of experimental medicine.

[27]  M. Denkinger,et al.  In Vivo Blockade of Macrophage Migration Inhibitory Factor Ameliorates Acute Experimental Autoimmune Encephalomyelitis by Impairing the Homing of Encephalitogenic T Cells to the Central Nervous System , 2003, The Journal of Immunology.

[28]  C. Auriault,et al.  Evidences of conformational changes in class II Major Histocompatibility Complex molecules that affect the immunogenicity. , 2002, Molecular immunology.

[29]  John David,et al.  Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Klein,et al.  The HLA system. Second of two parts. , 2000 .

[31]  J. Klein,et al.  The HLA system. First of two parts. , 2000, The New England journal of medicine.

[32]  G. Benedek,et al.  Determinants of the Peptide-induced Conformational Change in the Human Class II Major Histocompatibility Complex Protein HLA-DR1* , 2000, The Journal of Biological Chemistry.

[33]  G. Benedek,et al.  A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding. , 1999, Biochemistry.

[34]  Moldenhauer,et al.  Surface‐expressed invariant chain (CD74) is required for internalization of human leucocyte antigen‐DR molecules to early endosomal compartments , 1999, Immunology.

[35]  D. Wiley,et al.  Structure of a trimeric domain of the MHC class II‐associated chaperonin and targeting protein Ii , 1998, The EMBO journal.

[36]  R. Bucala,et al.  Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Rudensky,et al.  Subtle conformational changes induced in major histocompatibility complex class II molecules by binding peptides. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P. A. Peterson,et al.  Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. , 1998, Immunity.

[39]  Wiklund Ra,et al.  First of two parts , 1997 .

[40]  L. Stern,et al.  The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding. , 1997, Structure.

[41]  M. von Itzstein,et al.  A conformational study of the human and rat encephalitogenic myelin oligodendrocyte glycoprotein peptides 35-55. , 1997, European journal of biochemistry.

[42]  A. Vandenbark,et al.  Male SJL mice do not relapse after induction of EAE with PLP 139–151 , 1996, Journal of neuroscience research.

[43]  P. Cresswell.  Invariant Chain Structure and MHC Class II Function , 1996, Cell.

[44]  J. Bernhagen,et al.  Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). , 1994, Biochemistry.

[45]  B. Arp,et al.  HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells , 1994, Nature.

[46]  Jeffrey A. Shaman,et al.  An essential role for HLA–DM in antigen presentation by class II major histocompatibility molecules , 1994, Nature.

[47]  Don C. Wiley,et al.  Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.

[48]  J. Miller,et al.  MHC class II antigen processing: biology of invariant chain. , 1994, Current opinion in immunology.

[49]  P. van Endert,et al.  Human major histocompatibility complex class II invariant chain is expressed on the cell surface. , 1990, The Journal of biological chemistry.

[50]  Valeria Panebianco,et al.  Supplementary Figure 2 , 2012 .

[51]  P. Cresswell,et al.  Assembly, transport, and function of MHC class II molecules. , 1994, Annual review of immunology.

[52]  C Dosne Pasqualini,et al.  The HLA system. , 1979, Medicina.